Adalimumab Market By Disease (Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis & others), By Type (Adalimumab, Adalimumab Biosimilar), By End-Users (Hospitals, Specialty Clinics & Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2022-2027
Adalimumab Market Overview
Adalimumab Market Size is estimated to reach $5.1 billion by 2027. Furthermore, it is poised to grow at a CAGR of 5.1% over the forecast period of 2022-2027. Adalimumab is a monoclonal antibody and disease-modifying antirheumatic medication that acts by inactivating tumor necrosis factor-alpha. It is marketed under the brand names Humira and Exemptia, among others. The original adalimumab drug is sold under the brand name Humira. New versions of adalimumab are known as adalimumab biosimilars. Biosimilars are similar versions of original biological medicines. Adalimumab is a drug used to treat rheumatoid arthritis and ankylosing spondylitis which affects the musculoskeletal system, Crohn’s disease, ulcerative colitis, psoriatic arthritis, hidradenitis suppurativa, and other diseases. It was first introduced in the United States by Abbvie and was approved by the FDA in 2002. It is used to alleviate inflammation by acting on the immune system. The growing prevalence of arthritis and skin disorders, adoption of a sedentary lifestyle, and growing obese population are some of the factors driving the Adalimumab Market growth during the forecast period 2022-2027.
The report: “Adalimumab Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Adalimumab Market.
By Disease- Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis, and others.
By Type- Adalimumab, Adalimumab Biosimilar.
By End-Users- Hospitals, Specialty Clinics, and Others.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).
- Geographically, North America held a dominant market share in the year 2021 on account of the increasing prevalence of psoriasis arthritis, highly informed people knowing the benefits of adalimumab, and high healthcare expenditure. Asia-Pacific is expected to offer lucrative growth opportunities to the manufacturers owing to increasing prevalence of Crohn's disease and ulcerative colitis., demand for better healthcare facilities as well a boost in the investments done by government and private companies in pharma industry. The proliferation of Rheumatoid arthritis is predicted to augment the market growth during the forecast period of 2022-2027.
- The growing prevalence of arthritis and skin disorders is estimated to drive the market growth of the Adalimumab Market. High cost as well as lack side effects of adalimumab poses threat to the market growth.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Adalimumab Market Report.
Adalimumab Market: Market Share (%) by region, 2021
For more details on this report - Request for Sample
Adalimumab Market Segmentation Analysis- By Disease
Adalimumab Market based on the disease can be further segmented into Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis, and others. Rheumatoid arthritis held a dominant market share in the year 2021 and is estimated to be the fastest-growing, with a CAGR of 7.8% over the forecast period of 2022-2027. Rheumatoid arthritis is a chronic inflammatory disorder that affects several joints, especially the hands and feet. The immune system of the body targets its own tissue, such as joints and muscles and attacks the internal organs in extreme cases. According to the estimations of the World Health Organisation (WHO) in 2021, around 14 million people live with Rheumatoid arthritis. The inflammation caused by rheumatoid arthritis can cause harm to other parts of the body as well. Cigarette smoking and excessive weight increase the risk of Rheumatoid arthritis. As per the estimations of the World Obesity Federation, 2.7 billion adults will be overweight, over 1 billion affected by obesity, and 177 million adults will be severely affected by obesity by 2025, propelling the prevalence of rheumatoid arthritis.
Adalimumab Market Segmentation Analysis- By End User
Adalimumab Market based on end-user can be further segmented into Hospitals, Specialty Clinics, and others. The hospital's segment held a dominant market share in the year 2021 and is estimated to be the fastest-growing, with a CAGR of 6.1% over the forecast period of 2022-2027 owing to increased healthcare infrastructure’s spending by countries, technological advancements in the hospital industry and increasing prevalence of arthritis requiring hospitalizations. According to the Centers for Disease Control and Prevention, Osteoarthritis accounted for more than $16 billion of the combined cost for all hospitalizations in the U.S. in 2020. Moreover, as per the estimations of Cureus Journal of Medical science, more than 560,000 hospitalizations in the U.S. were owing to rheumatoid arthritis in 2020, propelling the growth of the hospital's segment.
Adalimumab Market Segmentation Analysis- By Geography
The Adalimumab Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the rest of the World. North America held a dominant market share of 33% in the year 2021 as compared to the other counterparts on account of increased awareness about the effectiveness of adalimumab in treating arthritis, rising prevalence of psoriasis arthritis, FDA approvals for adalimumab biosimilars, and high healthcare spending. According to the National Psoriasis Foundation, more than 8 million people in the U.S. have psoriasis.
However, Asia-Pacific is estimated to be the fastest-growing, with a CAGR of 7.2% over the forecast period of 2022-2027 on account of rising healthcare expenditure, demand for better healthcare facilities, and increasing prevalence of inflammatory bowel disease (IBD) which includes Crohn's disease and ulcerative colitis. IBD is getting more common, complex, and severe in Australia, according to Crohn's & Colitis. It affects about 1 in 250 adults aged 5 to 40. Crohn's disease or ulcerative colitis affects nearly 75,000 Australians, with the number expected to rise to 100,000 by 2022. Furthermore, the number of Canadians suffering from IBD is predicted to reach 400,000 by 2030, propelling market growth.
Adalimumab Market Drivers
The growing prevalence of arthritis disorders is boosting the market growth.
According to the CDC, 54.4 million US individuals have some type of arthritis, a number that is projected to rise to 78 million by 2040. Disorders associated with arthritis include inflammation of one or more joints, resulting in pain, swelling, and stiffness. Adalimumab is used to decrease the pain and swelling as well as slow down the progress of arthritis. Adalimumab is primarily used for treating active enthesitis-related arthritis, Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, Osteoarthritis, and others. Growing geriatric population, sedentary lifestyle, and growing prevalence of obesity increase the risk of psoriasis and rheumatoid arthritis. The increasing prevalence of Crown’s disease is estimated to propel the market growth as Crohn's disease increases the risk for arthritis. According to the Crohn's & Colitis Foundation, approximately 30% of Crohn's disease patients develop arthritis, thereby driving the Adalimumab Industry growth.
Skin Disorder Proliferation is Driving Market Growth
According to the World Health Organisation (WHO), around 900 million people in the world suffer from skin diseases at any given point in time. Adalimumab targets a protein in the body called tumor necrosis factor-alpha (TNF-alpha), which is a key player in the inflammatory process that triggers skin disorders including psoriasis. Psoriasis is a skin disorder that causes red, itchy scaly spots on the knees, elbows, trunk, and scalp. Adalimumab suppresses the hyperactive immune system response that triggers psoriasis. As per the estimations of the National Psoriasis Foundation, 125 million people worldwide which accounts for 2 to 3 percent of the total population, have psoriasis, propelling the market growth.
Adalimumab Market Challenges
Side effects and the high cost of adalimumab pose a threat to market growth.
Adalimumab costs around USD 2000-3000 per infusion, which makes it quite expensive for people living in low and middle-income countries. Furthermore, the side effects of adalimumab are estimated to impede the market growth. Some of the common side effects of adalimumab are fever, swollen glands, night sweats, general feeling of illness, joint and muscle pain, skin rash, easy bruising or bleeding, and others. Adalimumab can also induce a lethal kind of lymphoma or cancer of the liver, spleen, and bone marrow. This primarily occurs in teenagers and young men suffering from Crohn's disease or ulcerative colitis, hampering the market growth.
Adalimumab Market Competitive Landscape
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Adalimumab Market. The top 10- Adalimumab Market companies are-
- Croda International Plc
- AbbVie Inc
- Clariant AG
- Novartis AG
- AkzoNobel N.V
- F. Hoffmann-La Roche Ltd.
- Evonik Industries
- PolyOne Corporation
- Addcomp Holland
- In June 2021, Celltrion Healthcare won approval by European Commission for marketing its subcutaneous infliximab biosimilar, Remsima for new and existing RA patients and it launched Remsima in Canada for the treatment of adult patients with RA.
- In February 2021, Sandoz Canada, a Pharmaceutical and Medicine Manufacturing company launched an adalimumab biosimilar named Hyrimoz in Canada. On November 4, 2020, Health Canada approved Hyrimoz to treat nine of the 12 indications of the reference biological Humira.
- In February 2021, Japan-based Fujifilm Kyowa Kirin Biologics in partnership with US-based drugmaker Viatris announced the launch of an adalimumab biosimilar named Adalimumab Biosimilar 1 in Japan. The biosimilar was approved by Japan's regulatory body in June 2020 and it will be the country's first adalimumab biosimilar to be launched.